Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Brim Biotechnology Inc. has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are spread across 3 distinct examiners but only 2 distinct art units. This indicates that the 3 pending office actions are concentrated within the 2 distinct art units. For a practitioner, this suggests that while examiner-specific preferences will vary, the underlying art unit policies may be consistent across the 2 distinct art units identified in the data.
HELLMAN, KRISTINA M is the busiest examiner, managing 1 busiest examiner pending office action. With the total workload distributed among the examiners, no 1 individual handles all cases. This variety within the Biotechnology & Pharmaceuticals portfolio may lead to different prosecution styles being applied to the company's innovations. The strategy for this portfolio must remain flexible to accommodate the diverse approaches of the examiners involved in the 3 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HELLMAN, KRISTINA M | 1 | 65.3% | +55.3% |
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273962 | COMPOSITIONS COMPRISING PEDF-DERIVED SHORT PEPTIDES (PDSP) AND USES THEREOF | SABILA, MERCY HELLEN | 4d overdue |
| 18562810 | COMPOSITION COMPRISING PEDF-DERIVED SHORT PEPTIDE, PREPARATION METHOD THEREOF, AND USE THEREOF | HELLMAN, KRISTINA M | — |
| 17766250 | COMPOSITIONS COMPRISING PEDF-DERIVED SHORT PEPTIDES (PDSP) AND USES THEREOF | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562810 | COMPOSITION COMPRISING PEDF-DERIVED SHORT PEPTIDE, PREPARATION METHOD THEREOF, AND USE THEREOF | HELLMAN, KRISTINA M | 1654 | §103§112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18273962 | COMPOSITIONS COMPRISING PEDF-DERIVED SHORT PEPTIDES (PDSP) AND USES THEREOF | SABILA, MERCY HELLEN | 1654 | §103 | Non-Final OA | 4d overdue | Pending | Jul 24, 2023 |
| 17766250 | COMPOSITIONS COMPRISING PEDF-DERIVED SHORT PEPTIDES (PDSP) AND USES THEREOF | REYNOLDS, FRED H | 1658 | §103Other | Final Rejection | — | Pending | Apr 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial